- Eiger BioPharmaceuticals ( NASDAQ: EIGR ) on Wednesday said the European Commission had granted a marketing authorization to its treatment Zokinvy (lonafarnib) for progeria, which is a progressive genetic disorder that causes accelerated aging.
- The specific indication for which Zokinvy was approved was as a breakthrough therapy in children and young adults with Hutchinson-Gilford progeria syndrome and processing-deficient progeroid laminopathies.
- The European approval for Zokinvy is valid in all 27 EU member states as well as Iceland, Liechtenstein and Norway.
- EIGR says Zokinvy is the first and only treatment approved in Europe for progeria.
- The therapy was approved by the U.S. FDA in 2020.
- EIGR stock +2.8% to $8.73 in early trading.
For further details see:
European Commission approves Eiger BioPharmaceuticals' progeria therapy Zokinvy